B Parhami-Seren
Overview
Explore the profile of B Parhami-Seren including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
173
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Butenas S, Parhami-Seren B, Mann K
J Thromb Haemost
. 2008 Nov;
7(1):132-7.
PMID: 18983499
Background: It has been reported by multiple laboratories that the quantitation of factor (F)VIII by activity-based assays is influenced by the method, procedure and the quality of reagents used in...
2.
Butenas S, Parhami-Seren B, Gissel M, Gomperts E, Fass D, Mann K
Haemophilia
. 2008 Aug;
15(1):63-72.
PMID: 18691375
Several factor (F) VIII products of different origin and structure are being used for haemophilia A treatment worldwide. The assessment of FVIII concentration in these products is done using activity...
3.
Parhami-Seren B, Butenas S, Krudysz-Amblo J, Mann K
J Thromb Haemost
. 2006 Aug;
4(8):1747-55.
PMID: 16879217
The large number of conflicting reports on the presence and concentration of circulating tissue factor (TF) in blood generates uncertainties regarding its relevance to hemostasis and association with specific diseases....
4.
Brummel Ziedins K, Rivard G, Pouliot R, Butenas S, Gissel M, Parhami-Seren B, et al.
J Thromb Haemost
. 2004 Oct;
2(10):1735-44.
PMID: 15456484
Factor (F)VII deficiency is an autosomal recessive disorder for which a replacement therapy is not universally available; recombinant FVIIa has been utilized as a therapeutic substitute. As FVII competes with...
5.
Parhami-Seren B, Viswanathan M, Strong R, Margolies M
J Immunol
. 2001 Oct;
167(9):5129-35.
PMID: 11673524
Alanine scanning was used to determine the affinity contributions of 10 side chain amino acids (residues at position 50-60 inclusive) of H chain complementarity-determining region 2 (HCDR2) of the somatically...
6.
Monoclonal antibodies that distinguish between two related digitalis glycosides, ouabain and digoxin
Parhami-Seren B, Bell C, Margolies M, Haupert Jr G
J Immunol
. 1999 Oct;
163(8):4360-6.
PMID: 10510376
The exogenous digitalis glycosides, ouabain and digoxin, have been widely used in humans to treat congestive heart failure and cardiac arrhythmias. Several reports have also pointed to the existence of...
7.
Reed G, Houng A, Liu L, Parhami-Seren B, Matsueda L, Wang S, et al.
Proc Natl Acad Sci U S A
. 1999 Aug;
96(16):8879-83.
PMID: 10430864
Plasminogen (Pg) activators such as streptokinase (SK) save lives by generating plasmin to dissolve blood clots. Some believe that the unique ability of SK to activate Pg in the absence...
8.
Wong Y, Gill D, Parhami-Seren B, Short M, Sompuram S, Margolies M
J Immunol
. 1998 Jun;
160(12):5990-7.
PMID: 9637513
We previously showed that a single mutation at heavy (H) position 35 of Abs specific for p-azophenylarsonate (Ars) resulted in acquisition of binding to the structurally related hapten p-azophenylsulfonate (Sulf)....
9.
Parhami-Seren B, Keel T, Reed G
J Mol Biol
. 1997 Aug;
271(3):333-41.
PMID: 9268662
Though streptokinase (SK) is widely used to treat humans with thrombotic disease, it is antigenic and anti-SK antibody causes allergic reactions and neutralizes SK's therapeutic effects. To pinpoint the fine...
10.
Parhami-Seren B, Margolies M
J Immunol
. 1996 Sep;
157(5):2066-72.
PMID: 8757328
We showed previously that heavy chain gene junctional amino acid differences among unmutated p-azophenylarsonate (Ars) Abs that share a unique gene segment combination encoding these V regions, termed "canonical," alter...